162 related articles for article (PubMed ID: 24366744)
1. KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro.
Zeeman AM; van Amsterdam SM; McNamara CW; Voorberg-van der Wel A; Klooster EJ; van den Berg A; Remarque EJ; Plouffe DM; van Gemert GJ; Luty A; Sauerwein R; Gagaring K; Borboa R; Chen Z; Kuhen K; Glynne RJ; Chatterjee AK; Nagle A; Roland J; Winzeler EA; Leroy D; Campo B; Diagana TT; Yeung BK; Thomas AW; Kocken CH
Antimicrob Agents Chemother; 2014; 58(3):1586-95. PubMed ID: 24366744
[TBL] [Abstract][Full Text] [Related]
2. Azithromycin disrupts apicoplast biogenesis in replicating and dormant liver stages of the relapsing malaria parasites Plasmodium vivax and Plasmodium cynomolgi.
Amanzougaghene N; Tajeri S; Franetich JF; Ashraf K; Soulard V; Bigeard P; Guindo CO; Bouillier C; Lemaitre J; Relouzat F; Legrand R; Kocken CHM; Zeeman AM; Roobsoong W; Sattabongkot J; Yang Z; Snounou G; Mazier D
Int J Antimicrob Agents; 2024 May; 63(5):107112. PubMed ID: 38367843
[TBL] [Abstract][Full Text] [Related]
3. Probing the distinct chemosensitivity of Plasmodium vivax liver stage parasites and demonstration of 8-aminoquinoline radical cure activity in vitro.
Maher SP; Vantaux A; Chaumeau V; Chua ACY; Cooper CA; Andolina C; Péneau J; Rouillier M; Rizopoulos Z; Phal S; Piv E; Vong C; Phen S; Chhin C; Tat B; Ouk S; Doeurk B; Kim S; Suriyakan S; Kittiphanakun P; Awuku NA; Conway AJ; Jiang RHY; Russell B; Bifani P; Campo B; Nosten F; Witkowski B; Kyle DE
Sci Rep; 2021 Oct; 11(1):19905. PubMed ID: 34620901
[TBL] [Abstract][Full Text] [Related]
4. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta).
Dow GS; Gettayacamin M; Hansukjariya P; Imerbsin R; Komcharoen S; Sattabongkot J; Kyle D; Milhous W; Cozens S; Kenworthy D; Miller A; Veazey J; Ohrt C
Malar J; 2011 Jul; 10():212. PubMed ID: 21801400
[TBL] [Abstract][Full Text] [Related]
5. Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.
Campo B; Vandal O; Wesche DL; Burrows JN
Pathog Glob Health; 2015 May; 109(3):107-22. PubMed ID: 25891812
[TBL] [Abstract][Full Text] [Related]
6. Superior protection in a relapsing Plasmodium cynomolgi rhesus macaque model by a chemoprophylaxis with sporozoite immunization regimen with atovaquone-proguanil followed by primaquine.
Yongvanitchit K; Kum-Arb U; Limsalakpetch A; Im-Erbsin R; Ubalee R; Spring MD; Vesely BA; Waters N; Pichyangkul S
Malar J; 2024 Apr; 23(1):106. PubMed ID: 38632607
[TBL] [Abstract][Full Text] [Related]
7. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Meister S; Plouffe DM; Kuhen KL; Bonamy GM; Wu T; Barnes SW; Bopp SE; Borboa R; Bright AT; Che J; Cohen S; Dharia NV; Gagaring K; Gettayacamin M; Gordon P; Groessl T; Kato N; Lee MC; McNamara CW; Fidock DA; Nagle A; Nam TG; Richmond W; Roland J; Rottmann M; Zhou B; Froissard P; Glynne RJ; Mazier D; Sattabongkot J; Schultz PG; Tuntland T; Walker JR; Zhou Y; Chatterjee A; Diagana TT; Winzeler EA
Science; 2011 Dec; 334(6061):1372-7. PubMed ID: 22096101
[TBL] [Abstract][Full Text] [Related]
8. Extrahepatic exoerythrocytic forms of rodent malaria parasites at the site of inoculation: clearance after immunization, susceptibility to primaquine, and contribution to blood-stage infection.
Voza T; Miller JL; Kappe SH; Sinnis P
Infect Immun; 2012 Jun; 80(6):2158-64. PubMed ID: 22431651
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.
Roth A; Maher SP; Conway AJ; Ubalee R; Chaumeau V; Andolina C; Kaba SA; Vantaux A; Bakowski MA; Thomson-Luque R; Adapa SR; Singh N; Barnes SJ; Cooper CA; Rouillier M; McNamara CW; Mikolajczak SA; Sather N; Witkowski B; Campo B; Kappe SHI; Lanar DE; Nosten F; Davidson S; Jiang RHY; Kyle DE; Adams JH
Nat Commun; 2018 May; 9(1):1837. PubMed ID: 29743474
[TBL] [Abstract][Full Text] [Related]
10. Extended blood stage sensitivity profiles of
Christensen P; Cinzah R; Suwanarusk R; Chua ACY; Kaneko O; Kyle DE; Aung HL; Matheson J; Bifani P; Rénia L; Cook GM; Snounou G; Russell B
Antimicrob Agents Chemother; 2024 May; 68(5):e0028024. PubMed ID: 38587391
[TBL] [Abstract][Full Text] [Related]
11. Targeting Plasmodium PI(4)K to eliminate malaria.
McNamara CW; Lee MC; Lim CS; Lim SH; Roland J; Simon O; Yeung BK; Chatterjee AK; McCormack SL; Manary MJ; Zeeman AM; Dechering KJ; Kumar TS; Henrich PP; Gagaring K; Ibanez M; Kato N; Kuhen KL; Fischli C; Nagle A; Rottmann M; Plouffe DM; Bursulaya B; Meister S; Rameh L; Trappe J; Haasen D; Timmerman M; Sauerwein RW; Suwanarusk R; Russell B; Renia L; Nosten F; Tully DC; Kocken CH; Glynne RJ; Bodenreider C; Fidock DA; Diagana TT; Winzeler EA
Nature; 2013 Dec; 504(7479):248-253. PubMed ID: 24284631
[TBL] [Abstract][Full Text] [Related]
12. A Drug Repurposing Approach Reveals Targetable Epigenetic Pathways in
Maher SP; Bakowski MA; Vantaux A; Flannery EL; Andolina C; Gupta M; Antonova-Koch Y; Argomaniz M; Cabrera-Mora M; Campo B; Chao AT; Chatterjee AK; Cheng WT; Chuenchob E; Cooper CA; Cottier K; Galinski MR; Harupa-Chung A; Ji H; Joseph SB; Lenz T; Lonardi S; Matheson J; Mikolajczak SA; Moeller T; Orban A; Padín-Irizarry V; Pan K; Péneau J; Prudhomme J; Roesch C; Ruberto AA; Sabnis SS; Saney CL; Sattabongkot J; Sereshki S; Suriyakan S; Ubalee R; Wang Y; Wasisakun P; Yin J; Popovici J; McNamara CW; Joyner CJ; Nosten F; Witkowski B; Le Roch KG; Kyle DE
bioRxiv; 2024 Mar; ():. PubMed ID: 36778461
[TBL] [Abstract][Full Text] [Related]
13. Liver-targeted polymeric prodrugs delivered subcutaneously improve tafenoquine therapeutic window for malaria radical cure.
Pottenger AE; Roy D; Srinivasan S; Chavas TEJ; Vlaskin V; Ho DK; Livingston VC; Maktabi M; Lin H; Zhang J; Pybus B; Kudyba K; Roth A; Senter P; Tyson G; Huber HE; Wesche D; Rochford R; Burke PA; Stayton PS
Sci Adv; 2024 Apr; 10(16):eadk4492. PubMed ID: 38640243
[TBL] [Abstract][Full Text] [Related]
14. Lead optimization of imidazopyrazines: a new class of antimalarial with activity on Plasmodium liver stages.
Zou B; Nagle A; Chatterjee AK; Leong SY; Tan LJ; Sim WL; Mishra P; Guntapalli P; Tully DC; Lakshminarayana SB; Lim CS; Tan YC; Abas SN; Bodenreider C; Kuhen KL; Gagaring K; Borboa R; Chang J; Li C; Hollenbeck T; Tuntland T; Zeeman AM; Kocken CH; McNamara C; Kato N; Winzeler EA; Yeung BK; Diagana TT; Smith PW; Roland J
ACS Med Chem Lett; 2014 Aug; 5(8):947-50. PubMed ID: 25147620
[TBL] [Abstract][Full Text] [Related]
15. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission.
Kuhen KL; Chatterjee AK; Rottmann M; Gagaring K; Borboa R; Buenviaje J; Chen Z; Francek C; Wu T; Nagle A; Barnes SW; Plouffe D; Lee MC; Fidock DA; Graumans W; van de Vegte-Bolmer M; van Gemert GJ; Wirjanata G; Sebayang B; Marfurt J; Russell B; Suwanarusk R; Price RN; Nosten F; Tungtaeng A; Gettayacamin M; Sattabongkot J; Taylor J; Walker JR; Tully D; Patra KP; Flannery EL; Vinetz JM; Renia L; Sauerwein RW; Winzeler EA; Glynne RJ; Diagana TT
Antimicrob Agents Chemother; 2014 Sep; 58(9):5060-7. PubMed ID: 24913172
[TBL] [Abstract][Full Text] [Related]
16. Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures.
Dembélé L; Franetich JF; Lorthiois A; Gego A; Zeeman AM; Kocken CH; Le Grand R; Dereuddre-Bosquet N; van Gemert GJ; Sauerwein R; Vaillant JC; Hannoun L; Fuchter MJ; Diagana TT; Malmquist NA; Scherf A; Snounou G; Mazier D
Nat Med; 2014 Mar; 20(3):307-12. PubMed ID: 24509527
[TBL] [Abstract][Full Text] [Related]
17. Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents.
Ng PS; Manjunatha UH; Rao SP; Camacho LR; Ma NL; Herve M; Noble CG; Goh A; Peukert S; Diagana TT; Smith PW; Kondreddi RR
Eur J Med Chem; 2015 Dec; 106():144-56. PubMed ID: 26544629
[TBL] [Abstract][Full Text] [Related]
18. Identification of covalent active site inhibitors of dengue virus protease.
Koh-Stenta X; Joy J; Wang SF; Kwek PZ; Wee JL; Wan KF; Gayen S; Chen AS; Kang C; Lee MA; Poulsen A; Vasudevan SG; Hill J; Nacro K
Drug Des Devel Ther; 2015; 9():6389-99. PubMed ID: 26677315
[TBL] [Abstract][Full Text] [Related]
19. Increased Vancomycin Susceptibility in Mycobacteria: a New Approach To Identify Synergistic Activity against Multidrug-Resistant Mycobacteria.
Soetaert K; Rens C; Wang XM; De Bruyn J; Lanéelle MA; Laval F; Lemassu A; Daffé M; Bifani P; Fontaine V; Lefèvre P
Antimicrob Agents Chemother; 2015 Aug; 59(8):5057-60. PubMed ID: 26033733
[TBL] [Abstract][Full Text] [Related]
20. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
